Crism Therapeutics: Phase 2 Clinical Trial Progress Update
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
25 June 2026
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Phase 2 Clinical Trial Progress Update
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, provides an update on its Phase 2 clinical trial of irinotecan ChemoSeed® in patients with glioblastoma.
The Company confirms that all product manufacturing, quality, regulatory and study start-up activities required for patient treatment have been completed and that site activation is at an advanced stage. Multiple clinical support departments have completed their individual assessments and sign-off procedures, and a Site Initiation Visit ("SIV"), the final procedural step before the site can be activated for patient recruitment, is planned for late July. This represents significant progress and the Company will provide further updates regarding patient recruitment and dosing following the SIV.
The Company is fully funded to complete Part 1 of the trial and is well positioned to initiate Part 2 on completion. The Board looks forward to providing shareholders with further updates regarding the trial and the clinical development of ChemoSeed in due course.
-Ends-
Enquiries:
Company
Nomad and Broker
Financial PR
CRISM Therapeutics Corporation
S.P. Angel Corporate Finance LLP
Burson Buchanan
Andrew Webb, Executive Chairman
Chris McConville, CSO
David Hignell
Vadim Alexandre
Adam Cowl
Henry Harrison Topham
Jamie Hooper
CRISM@buchanancomms.co.uk
via Burson Buchanan
+44 (0) 20 3470 0470
+44 (0) 20 7466 5000
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
For more information please visit: https://www.crismtherapeutics.com/
The Company's LEI is 213800XFW6MKVCHHPW88.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDUPDDZGZVRDNGVZM
